Filing Flows › NovoCure (NVCR) › R&D spending
NovoCure (NVCR) R&D spending by quarter
NovoCure's R&D spending was $58.1M in Q3 2026 (third quarter 2026), +13% from Q2 2026. Over the last 7 quarters it ranged from $51.4M (Q2 2026) to $60.9M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $58.1M | +13% | +8% |
| Q2 2026 | $51.4M | -12% | -8% |
| Q1 2026 | $58.3M | -4% | +8% |
| Q4 2025 | $60.9M | +13% | — |
| Q3 2025 | $54.0M | -3% | — |
| Q2 2025 | $55.8M | +4% | — |
| Q1 2025 | $53.8M | — | — |
Q3 2026 at a glance
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is NovoCure's R&D spending?
NovoCure's R&D spending was $58.1M in Q3 2026 (third quarter 2026), +13% from Q2 2026.
How has NovoCure's R&D spending changed?
Over the last 7 quarters it ranged from $51.4M (Q2 2026) to $60.9M (Q4 2025).